Invivyd, Inc.

Analysis for Ticker: IVVD

Invivyd Inc is a commercial-stage company that develops monoclonal antibodies to prevent and treat viral infections like COVID and measles. While they promote their platform as a scientific breakthrough, the internal math tells a story of a business that has swallowed 954,5$ million in accumulated losses. Think of the company as a giant wallet with a hole in the bottom. Every time an investor puts money into the wallet, the managers use that money to pay their friends at other companies or they print new membership cards called shares to pay themselves. Because they keep printing more of these cards, the ones you already have become worth a smaller and smaller piece of the wallet. It is a mathematical trap where the business is actually worth only 0,43$ per share based on its real assets, even while it tries to sell itself for much more.